Aridhia's Data Platform Used in Major European Research Collaboration to Tackle Alzheimer's Dementia

AridhiaAridhia has announced that it is among 36 organisations behind a ground-breaking Innovative Medicines Initiative research programme that aims to build a platform for efficient testing of innovative treatments for the prevention of Alzheimer's dementia.

Aridhia's data and analytics platform, AnalytiXagility, has been selected for use in the European Prevention of Alzheimer's Dementia (EPAD) project, a powerful research collaboration between European organisations in the public and private sectors which, unlike previous projects, focuses on prevention of dementia in the early stages of the disease.

The project will collaborate with existing cohorts to create a register, identifying 24,000 people across Europe who may be at risk of developing the disease later in life. 6,000 of these people will be invited to join EPAD's cohort of 'at risk' subjects to undergo standardised tests and follow-ups. Of these, approximately 1,500 people will be selected to take part in EPAD's proof of concept adaptive trials of innovative drugs.

Rodrigo Barnes, Chief Technology Officer at Aridhia, said that AnalytiXagility has been chosen because it offers a strong collaborative platform that is accessible to all of the consortium partners and is able to carry out advanced data analytics that can interrogate any kind of data.

"AnalytiXagility offers EPAD a flexible working environment that is collaborative, neutral and has the ability to carry out advanced data analytics during complex trials.

"It will be used as part of a trial engine for the EPAD cohort of 6,000 subjects and the further 1,500 participants who will be asked to take part in the project’s proof of concept adaptive trials of drug candidates or drug combinations that have been specially designed to prevent Alzheimer's dementia.

"With no cure for Alzheimer's and little in the way of treatment, it is vital that we understand and learn how to prevent Alzheimer’s dementia when in its early phases."

The University of Edinburgh is working with Aridhia to trial the EPAD cohort. Professor Craig Ritchie, one of the project’s co-ordinators who is based at the University said: "EPAD is a game-changing project. There is commitment from a wide range of organisations across academia, pharma and public health, to get to the root causes of dementia, to understand how the disease develops over the decades before symptoms become visible, and treat patients at an early stage."

"The EPAD model gives us the opportunity to work together to understand who is more likely the get the disease and how they can be treated early, and effectively."

EPAD promises to deliver a more efficient research model which can streamline the recruitment of patients and enable likely drug candidates to be accelerated straight into Phase III trials, the last stage before a new drug is licenced for use.

Furthermore, all data collected from the cohort will be made public to allow researchers the chance to improve their understanding of the disease, especially in pre-symptomatic phases.

Aridhia's involvement in EPAD cements its commitment to globally significant collaborative research projects, and to addressing one of society’s most challenging diseases. Earlier this year the company announced that AnalytiXagility has been chosen to underpin the three year Moneta Research project, supporting their research into identifying people most likely to develop Alzheimer's dementia.

About Aridhia Informatics
Founded in 2007, Aridhia is a world-leading clinical and translational informatics company developing technology and capability that accelerates the translation of precision medicine and biomedical research into clinical practice. Operating internationally on projects in England, Scotland, Australia, and across Europe, Aridhia works closely with governments, health organisations, research collaborations and academic institutions to transform how care is delivered.

Based in Edinburgh and Glasgow, Aridhia has a 60-strong multidisciplinary team of data scientists, information governance specialists, computer scientists, software developers and healthcare experts.

About the Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA.

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution.

Most Popular Now

Virtual Humans Help Aspiring Doctors Lea…

For medical student Katie Goldrath, the first time delivering difficult health news came when she had to tell a young woman named Robin and her mom, Delmy, that Robin had...

Read more

Siemens Healthineers Presents Solutions …

Under the motto "More Networking. More Digitalization. More Value" Siemens Healthineers, the separately managed healthcare business of Siemens AG, is presenting its solutions for the digitalization of healthcare at the...

Read more

'Smart Contact Lens Sensor' for Diabetic…

A recent study, affiliated with Ulsan National Institute of Science and Technology (UNIST), South Korea, has proposed the possibility of in situ human health monitoring simply by wearing a contact...

Read more

ECDC Report Shows Strong Potential of E-…

Twenty one EU/EEA countries have developed or are in the process of developing systems to digitally record information about vaccination, according to a new "ECDC survey report on immunisation information...

Read more

2017 eHealth Competition Awards SilverCl…

The eHealth Competition is an initiative that rewards the best digital health solutions produced by SMEs across Europe. This edition has been supported by Astrazeneca, Ship2B and Younoodle. This competition...

Read more

Devicare Raises 3 Million Euros in its C…

Devicare, a company specializing in innovative medical devices for chronic home care patients under Remote Patient Monitoring (RPM), has closed out a seed round of 3 million euros. This funding...

Read more

Successful Conclusion to conhIT 2017, th…

25 - 27 April 2017, Berlin, Germany. As conhIT, which took place from 25 to 27 April in Berlin, came to a close, 500 exhibitors, 9,500 participants from around the world...

Read more

Scopis Introduces the First Mixed-Realit…

Scopis, a company specializing in surgical navigation and medical augmented and mixed reality technologies, announced today the launch of its newest development, the Holographic Navigation Platform for use in surgery...

Read more

IMS MAXIMS Launches Vital Signs Mobile A…

Clinical technology specialist IMS MAXIMS will be launching its fully integrated vital signs application at eHealth Week on 3rd and 4th May in Olympia, London. Delegates will be the first...

Read more

Immunisation Information Systems in the …

Immunisation information systems (IIS) are defined as confidential, population-based, computerised databases that record all immunisation doses administered by participating providers to persons residing within a given geopolitical area. At the...

Read more

Abbott Announces CE Mark and First Use o…

Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm RxTM Insertable Cardiac Monitor (ICM), the world's first smartphone compatible ICM that will help physicians identify...

Read more

m.Doc Connects Mobile Ultrasound to its …

Holistic medical services at the "point of care" - anytime and anywhere! That is what the Cologne-based start-up m.Doc is promising to deliver, via software that enables the transfer of...

Read more
(HEALTH IT) SPACE - Take a look at who has just Joined